Thomas Elnick’s Post

We're excited to announce that we have today initiated coverage 🔍 📖 on The Craneware Group (#CRW). Craneware is the market leader in value cycle SaaS provision in the US with a 40% market penetration and the ambition to become ubiquitous in US hospitals. The shackles of Covid disruption, digestion of the Sentry acquisition, and the transitioning of its customers to the fully cloud based Trisus platform, have fallen away and opened up new sales opportunities for the group. While the shares have out-performed strongly, multiples look reasonable compared with peers. We calculate a DCF based fair value of 2,541p, 15% above the current share price which could easily prove conservative on stronger medium term revenue growth. Craneware sits in the sweet spot of the structural transformation underway in the US healthcare market to value-based care which is currently also the hottest area of healthcare SaaS M&A activity. If you'd like to learn more about Craneware's story, you can find the note, for free, on the portal on our website, as well as across all the usual platforms such as Bloomberg, Refinitiv, FactSet, Research Tree, etc. below. https://lnkd.in/e9HYn94d Thanks to Colin Smith for the insight, time, and effort! #research #equityresearch #equities #investmentmanagement #capitalmarkets #software #healthcare

We’re fortunate to live in an era of rapid innovation in life science tools. Success today means being laser-focused—not just on innovation, but on how to commercialize with precision. This is why we created the i5Bio Impact Scorecard. By assessing your company’s strengths and opportunities for improvement across five critical impact areas, we help you follow a known path to commercialization success. Ready to focus your efforts and stand out? https://lnkd.in/e2WxZUXr.

Do you want to stay ahead of the curve with insights that truly matter to your business? Customized research is available for REDI Cincinnati investors. We understand that every business has unique data needs. That's why we go beyond mere numbers, tapping into a vast array of sources to craft research tailored to your specific requirements. Discover the difference customized research can make! Learn more at https://lnkd.in/gvuCp9CA . #BusinessGrowth #DataDriven #CustomizedResearch #BusinessInsights #Innovation

I am delighted to author a whitepaper introducing Defined Outcome strategies. These strategies have gained popularity in the recent years, with more than 200 ETFs traded on the US markets and an aggregate AUM of over $50 billion. #DefinedOutcome #InvestmentStrategies #options #ETFs #buffers #incomegeneration #indices

How it started and how it's going: Figshare as an institutional repository... 💡 Watch our on-demand webinar all about how the Figshare platform has evolved to support institutions looking to share, showcase and manage all of their research outputs. ✨ The session features an overview of the beginnings of Figshare from our founder, Mark Hahnel, followed by a summary from Andrew Mckenna-Foster of the important features that make us a leading provider of institutional repository infrastructure. ⚙ Catch up now: https://lnkd.in/eT4xedUb Digital Science #InstitutionalRepository #Repository #OpenResearch

At Eleveight, our mission is to empower clients with informed, sustainable decision-making. A crucial part of this is conducting rigorous secondary and primary research to uncover pivotal decision-making insights. Each time we see "Source: Eleveight research," we're advancing toward our goal. Excitingly, we're sharing key insights from the InsureTek Middle East Report, powered by Turtlefin. Stay tuned for more insights under "Source: Eleveight." 😊 Scan the QR code at the end to access the full report! Deepika Asthana Eleveight #InsuranceMarketResearch #strategyconsulting #PrimaryResearch

The Aquestive management team will participate in a fireside chat at the Citizens JMP Life Sciences Conference on May 13, 2024, at 11:30 am ET. Attendees can access the live webcast through the "Events and Presentations" section of the Investors page on the Aquestive corporate website. For those unable to join the live session, a recorded version will be available for on-demand viewing for 30 days following the conference. For more information, read our full press release linked in comments below. #AQST, #CitizensJMP, #investors

Biotech Equity Research: Tracking The Promise (And Risk) Of Early Stage Companies Navigating The Public Markets October 3, 2024, 3:00 – 4:00 p.m. EST Speaker: Benjamin J. Burnett, PhD, Managing Director, Equity Research, Stifel Investment Services Ben Burnett, Biotech Equity Research Analyst at Stifel will discuss the intersection of early stage life science companies and finance. We plan to cover recent capital market trends and forecasts, timing the market, and what it takes to become (and be) a public company. Balancing innovation with capital needs requires a good understanding of how and when to access capital, and whether or not this is more easily done as a private or public company. We plan to delve into these concepts in detail and walk through informative case studies of both success and failure.  Zoom Registration: https://lnkd.in/e-hHmpN7

AEA's April Newsletter is here. Read articles by Mark Brigman, Ph.D., SPLP, #Partnernomics, Warrick Cramer, #Kyndryl, Chris Webber and Howard Epstein from Accelerating Ecosystems Associates (AEA). One of AEA's market predictions is highlighted. Find the link to the recording of our April 11th Webinar on Maximizing Industrial Companies Ecosystems in an Era of Market Disruption featuring Eva Schoenleitner, Shiraz Mishra, and Chris Webber.